Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Hormone therapy and ovarian cancer – Authors’ reply

Users of menopausal hormone therapy are at greater risk of developing ovarian cancer than otherwise similar non-users. Our meta-analyses1 of virtually all the available epidemiological evidence showed a highly significantly increased risk of ovarian cancer in current users of menopausal hormone therapy; the excess risk declined after hormone use ceased, although a small excess persisted for about a decade after stopping long-duration use.1 In the few studies of fatal ovarian cancer, findings were typical of those reported for incident disease.